TP63 and small cell lung carcinoma: Genomic alterations shared by both patients including TP53 mutations, deletion (M7) or LOH (M9) of RB1, amplification of PIK3CA, PTEN, KRAS, SOX2, DVL3, and TP63. Most of these have also been implicated in SCLC [18–20].